You are here

Next-Generation Antibody Discovery and Development Technology

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44CA187852-02A1
Agency Tracking Number: R44CA187852
Amount: $1,570,238.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PAR13-327
Timeline
Solicitation Year: 2013
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-09-23
Award End Date (Contract End Date): 2019-08-31
Small Business Information
409 ILLINOIS ST
San Francisco, CA 94158-2509
United States
DUNS: 963285189
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAVID JOHNSON
 (415) 978-2101
 djohnson@gigagen.com
Business Contact
 DAVID JOHNSON
Phone: (415) 278-2101
Email: djohnson@gigagen.com
Research Institution
N/A
Abstract

PROJECT SUMMARY
Project TitleNext Generation Antibody Discovery and Development Technology
OrganizationGigaGen IncPIDavid SJohnsonPh DDespite an enormous investment in novel therapiescancer still accounts forof US deathskilling andgtpeople every dayFor exampleonlyof pancreatic cancer patients andof lung cancer patients
survive one year after diagnosisAdditionallyoncology treatments cost $billion per year in the USand are
expected to grow atper year throughMonoclonal antibodiesmAbsare now the biological agents of choice for cancer therapyThree of the top six
grossing therapeutics worldwidebevacizumabrituximaband trastuzumabare oncology mAbsTodaymost
mAb discovery programs use either some flavor of single chain variable fragmentscFvdisplay or mouse
immunization followed by hybridoma isolationDisplay technologies like phage display have tremendous ease
of usewhich enables Randamp D programs to screen through billions of antibodies in parallelUnlike conventional
phage display technologiesmouse immunizations produce fully natural antibodieswhich are often easier to
develop than antibodies discovered through displayThough display and mouse immunizations have produced breakthrough therapeutic antibodiesRandamp D programs
are always looking for fasterdeeperand more efficient antibody technologiesThe Specific Aim of this IMAT
Phase II SBIR project is to develop GigaLinka next generation high throughput molecular technology for
discovery and development of oncology drugs from mammalian B cell repertoiresGigaLinkis the only
technology that uses primary B cells to make millionsto billions diverse DNA libraries of antibodiesand then
expresses the DNA libraries as protein for affinity screening and antigen discoveryAs a DNA based
technologyGigaLinkuniquely enables massively parallel antibody screeningengineeringand
developmentA successful IMAT Phase II SBIR project will show that the GigaLinkantibody Randamp D platform can help our
customers understand basic tumor immunology and discover and develop therapeutic antibody candidatesWe will use the profits from GigaLinkservice revenues plus venture capital to build our own internal
programs for oncology therapeutic antibody discovery PROJECT NARRATIVE
Project TitleNext Generation Antibody Discovery and Development Technology
OrganizationGigaGen IncPIDavid SJohnsonPh DBetter methods for discovery of antibodies could eventually lead to drugs for treatment of a variety of diseases
and conditionsincluding cancerWe are building a novel technology that uses microfluidics and DNA
sequencing to capture and characterize new therapeutic antibodies from immune cells in human and mouse
blood

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government